-+ 0.00%
-+ 0.00%
-+ 0.00%

Spero Therapeutics And GSK Phase 3 PIVOT-PO Data Show Tebipenem Hydrobromide's Potential As The First Oral Carbapenem Antibiotic For Complicated Urinary Tract Infections

Benzinga·10/21/2025 06:14:49
Listen to the news
  • Data presented at IDWeek 2025 after study stopped early for efficacy
  • Primary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment1
  • Data will be shared with regulatory authorities to support regulatory filings